Lu Yuwen, Lu Yifei, Li Baobao, Liu Jiazhen, Wang Lixin, Zhang Lianyang, Li Yang, Zhong Qiu
Department of Laboratory Medicine, Daping Hospital, Army Medical University, Chongqing, China.
State Key Lab of Trauma, Burn and Combined Injury, Medical Center of Trauma and War Injury, Daping Hospital, Army Medical University, Chongqing, China.
Front Microbiol. 2023 Sep 29;14:1267786. doi: 10.3389/fmicb.2023.1267786. eCollection 2023.
infection has long been a serious concern in the medical field, with methicillin-resistant (MRSA) posing a considerable challenge to public health. Given the escalating bacterial resistance and the favorable biosafety and environmental properties of phages, the resurgence of phage therapy offers a promising alternative to antibiotics.
In this study, we isolated and characterized a MRSA phage named StAP1 from a Chinese hospital. Phenotypic and molecular analyses revealed its broad-spectrum characteristics, genomic background, and potential application in MRSA infection treatment.
Morphological examination classified the phage as a member of the phage family, displaying a typical hexagonal head and a slender fibrous tail. Genomic analysis unveiled a size of ~144,705 bp for the StAP1 genome, encompassing 215 open reading frames (ORFs). The one-step growth curve demonstrated a 20-min incubation period for the phage, with an optimal multiplicity of infection (MOI) of 0.1. Moreover, StAP1 exhibited stability across a wide range of temperatures and pH levels. Further investigation of its broad-spectrum characteristics confirmed its ability to effectively infect all staphylococcal cassette chromosomal mec (SCCmec) types found in MRSA strains, notably displaying a remarkable lysis rate of 76.7% against the prevalent ST239 strain in China. studies show cased significant efficacy of the StAP1 phage against MRSA infection.
Overall, StAP1 phage presents a broad infection spectrum and exhibits strong lytic effects on various MRSA strains, highlighting its tremendous potential as a powerful tool for MRSA infection treatment.
感染长期以来一直是医学领域的一个严重问题，耐甲氧西林金黄色葡萄球菌（MRSA）对公共卫生构成了相当大的挑战。鉴于细菌耐药性的不断升级以及噬菌体良好的生物安全性和环境特性，噬菌体疗法的复兴为抗生素提供了一种有前景的替代方案。
在本研究中，我们从一家中国医院分离并鉴定了一种名为StAP1的MRSA噬菌体。表型和分子分析揭示了其广谱特性、基因组背景以及在MRSA感染治疗中的潜在应用。
形态学检查将该噬菌体归类为噬菌体家族的一员，具有典型的六边形头部和细长的纤维状尾部。基因组分析显示StAP1基因组大小约为144,705 bp，包含215个开放阅读框（ORF）。一步生长曲线表明该噬菌体的潜伏期为20分钟，最佳感染复数（MOI）为0.1。此外，StAP1在广泛的温度和pH水平范围内表现出稳定性。对其广谱特性的进一步研究证实，它能够有效感染MRSA菌株中发现的所有葡萄球菌盒式染色体mec（SCCmec）类型，特别是对中国流行的ST239菌株显示出76.7%的显著裂解率。研究表明StAP1噬菌体对MRSA感染具有显著疗效。
总体而言，StAP1噬菌体具有广泛的感染谱，对各种MRSA菌株表现出强烈的裂解作用，突出了其作为MRSA感染治疗有力工具的巨大潜力。
